Open Access Case Report Article ID: AHCRR-7-136

    Hemophagocytic lymphohistiocytosis secondary to epstein-barr virus reactivation in a patient with COVID-19

    Nurfiza Ladak*, Kenneth Csehak, Justin Chan and Farnoush Moen

    Hemophagocytic lymphohistiocytosis (HLH) in coronavirus disease 2019 (COVID-19) is a recognized complication of severe illness. However, this phenomenon has been reported most often in the setting of acute infection. Here we present a case of a patient with a history of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection that subsequently developed HLH weeks after treatment of COVID-19 and discharges from the hospital. Upon re-admission, work-up demonstrated the patient was experiencing Epstein-Barr virus (EBV) reactivation. As EBV infection is a known etiological trigger of HLH, this case provides an alternative mechanism for HLH seen in patients with a history of COVID-19 infection who present after the resolution of acute symptomatology. 


    Published on: Feb 16, 2022 Pages: 6-8

    Full Text PDF Full Text HTML DOI: 10.17352/ahcrr.000036
    CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat


    Pinterest on AHCRR